Upadacitinib (ABT-494)

DRUG3 trials

Sponsors

AbbVie, Peking University People's Hospital

Conditions

Atopic DermatitisPrimary Sjögren's Syndrome (pSS)Ulcerative Colitis (UC)

Phase 1

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

CompletedNCT03646604

AbbVieAtopic Dermatitis

Start: 2019-01-31End: 2024-08-29Updated: 2025-02-10

Phase 2

Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome

Not yet recruitingNCT06862284

Peking University People's HospitalPrimary Sjögren's Syndrome (pSS)

Start: 2025-03-10End: 2027-08-31Target: 30Updated: 2025-03-11

Phase 3

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

Active, not recruitingNCT03006068

AbbVieUlcerative Colitis (UC)

Start: 2017-01-31End: 2027-07-31Target: 950Updated: 2026-01-12

Related Papers

DOP056 Efficacy and Safety of Upadacitinib After 5 Years of Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Analysis From the Phase 3 U-ACTIVATE Open-Label Extension Study

Journal of Crohn s and Colitis2026-01-01

Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study.

2025-06-017 citations

DOP002 Efficacy and safety of upadacitinib after 4 years of treatment in patients with moderately to severely active ulcerative colitis: interim long-term data from the phase 3 open-label extension study (U-ACTIVATE)

Journal of Crohn s and Colitis2025-01-013 citations

Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis.

2024-08-134 citations